{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T06:07:58Z","timestamp":1790402878627,"version":"4.1.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2024,9,28]],"date-time":"2024-09-28T00:00:00Z","timestamp":1727481600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,9,28]],"date-time":"2024-09-28T00:00:00Z","timestamp":1727481600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1038\/s41375-024-02425-1","type":"journal-article","created":{"date-parts":[[2024,9,28]],"date-time":"2024-09-28T03:02:30Z","timestamp":1727492550000},"page":"2644-2652","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Characterization of myeloproliferative neoplasms based on genetics only and prognostication of transformation to blast phase"],"prefix":"10.1038","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5083-9838","authenticated-orcid":false,"given":"Wencke","family":"Walter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niroshan","family":"Nadarajah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2432-8898","authenticated-orcid":false,"given":"Stephan","family":"Hutter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heiko","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6333-5049","authenticated-orcid":false,"given":"Claudia","family":"Haferlach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6452-2874","authenticated-orcid":false,"given":"Wolfgang","family":"Kern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0196-2837","authenticated-orcid":false,"given":"Torsten","family":"Haferlach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9038-3265","authenticated-orcid":false,"given":"Manja","family":"Meggendorfer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,28]]},"reference":[{"key":"2425_CR1","doi-asserted-by":"crossref","unstructured":"Cree IA. The WHO classification of haematolymphoid tumours. Leukemia. 2022;36:1701\u20132.","DOI":"10.1038\/s41375-022-01625-x"},{"key":"2425_CR2","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","volume":"36","author":"JD Khoury","year":"2022","unstructured":"Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF. et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms. Leukemia. 2022;36:1703\u201319.","journal-title":"Leukemia"},{"key":"2425_CR3","doi-asserted-by":"publisher","first-page":"2725","DOI":"10.1182\/blood-2012-10-464248","volume":"121","author":"JA Kennedy","year":"2013","unstructured":"Kennedy JA, Atenafu EG, Messner HA, Craddock KJ, Brandwein JM, Lipton JH. et al. Treatment outcomes following leukemic transformation in Philadelphia-negative myeloproliferative neoplasms. Blood. 2013;121:2725\u201333.","journal-title":"Blood"},{"key":"2425_CR4","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1182\/blood-2004-07-2864","volume":"105","author":"RA Mesa","year":"2005","unstructured":"Mesa RA, Li CY, Ketterling RP, Schroeder GS, Knudson RA, Tefferi A. Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases. Blood. 2005;105:973\u20137.","journal-title":"Blood"},{"key":"2425_CR5","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1158\/1078-0432.CCR-12-2087","volume":"19","author":"HJ Lee","year":"2013","unstructured":"Lee HJ, Daver N, Kantarjian HM, Verstovsek S, Ravandi F. The role of JAK pathway dysregulation in the pathogenesis and treatment of acute myeloid leukemia. Clin Cancer Res. 2013;19:327\u201335.","journal-title":"Clin Cancer Res"},{"key":"2425_CR6","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1182\/blood-2014-05-579136","volume":"124","author":"A Tefferi","year":"2014","unstructured":"Tefferi A, Guglielmelli P, Larson DR, Finke C, Wassie EA, Pieri L. et al. Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. Blood. 2014;124:2507\u201313.","journal-title":"Blood"},{"key":"2425_CR7","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1016\/j.mayocp.2017.05.010","volume":"92","author":"M Yogarajah","year":"2017","unstructured":"Yogarajah M, Tefferi A. Leukemic transformation in myeloproliferative neoplasms: a literature review on risk, characteristics, and outcome. Mayo Clin Proc. 2017;92:1118\u201328.","journal-title":"Mayo Clin Proc"},{"key":"2425_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-018-0054-y","volume":"8","author":"T Barbui","year":"2018","unstructured":"Barbui T, Thiele J, Gisslinger H, Kvasnicka HM, Vannucchi AM, Guglielmelli P. et al. The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion. Blood Cancer J. 2018;8:15.","journal-title":"Blood Cancer J"},{"key":"2425_CR9","unstructured":"WHO. WHO Classification of Tumours Editorial Board. Haematolymphoid tumours. WHO classification of tumours. 5th ed. Vol. 11: World Health Organization; 2024. https:\/\/tumourclassification.iarc.who.int\/chapters\/63."},{"key":"2425_CR10","doi-asserted-by":"crossref","unstructured":"Haferlach T. H\u00e4matologische Erkrankungen. 3rd ed. Berlin, Heidelberg:Springer; 2020.","DOI":"10.1007\/978-3-662-59547-3"},{"key":"2425_CR11","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/sj.leu.2402329","volume":"16","author":"C Schoch","year":"2002","unstructured":"Schoch C, Schnittger S, Bursch S, Gerstner D, Hochhaus A, Berger U. et al. Comparison of chromosome banding analysis, interphase- and hypermetaphase-FISH, qualitative and quantitative PCR for diagnosis and for follow-up in chronic myeloid leukemia: a study on 350 cases. Leukemia. 2002;16:53\u201359.","journal-title":"Leukemia"},{"key":"2425_CR12","doi-asserted-by":"crossref","unstructured":"McGowan-Jordan J, Simons A, Schmid M. ISCN 2016: an international system for human cytogenomic nomenclature (2016). Basel, Switzerland: Karger International; 2016.","DOI":"10.1159\/isbn.978-3-318-06861-0"},{"key":"2425_CR13","doi-asserted-by":"crossref","unstructured":"Delic S, Rose D, Kern W, Nadarajah N, Haferlach C, Haferlach T. et al. Application of an NGS-based 28-gene panel in myeloproliferative neoplasms reveals distinct mutation patterns in essential thrombocythaemia, primary myelofibrosis and polycythaemia vera. Br J Haematol. 2016;175:419\u201326.","DOI":"10.1111\/bjh.14269"},{"key":"2425_CR14","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1038\/sj.leu.2401773","volume":"14","author":"S Schnittger","year":"2000","unstructured":"Schnittger S, Kinkelin U, Schoch C, Heinecke A, Haase D, Haferlach T. et al. Screening for MLL tandem duplication in 387 unselected patients with AML identify a prognostically unfavorable subset of AML. Leukemia. 2000;14:796\u2013804.","journal-title":"Leukemia"},{"key":"2425_CR15","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1182\/blood.V100.1.59","volume":"100","author":"S Schnittger","year":"2002","unstructured":"Schnittger S, Schoch C, Dugas M, Kern W, Staib P, Wuchter C. et al. Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood. 2002;100:59\u201366.","journal-title":"Blood"},{"key":"2425_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-38408-3","volume":"9","author":"Y Wang","year":"2019","unstructured":"Wang Y, Richter L, Becker M, Amador C, Hyde RK. IL1RL1 is dynamically expressed on Cbfb-MYH11(+) leukemia stem cells and promotes cell survival. Sci Rep. 2019;9:1729.","journal-title":"Sci Rep"},{"key":"2425_CR17","doi-asserted-by":"crossref","unstructured":"Anelli L, Zagaria A, Specchia G, Albano F. The JAK2 GGCC (46\/1) Haplotype in myeloproliferative neoplasms: causal or random? Int J Mol Sci. 2018;19:1152.","DOI":"10.3390\/ijms19041152"},{"key":"2425_CR18","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1056\/NEJMoa1716614","volume":"379","author":"J Grinfeld","year":"2018","unstructured":"Grinfeld J, Nangalia J, Baxter EJ, Wedge DC, Angelopoulos N, Cantrill R. et al. Classification and personalized prognosis in myeloproliferative neoplasms. N Engl J Med. 2018;379:1416\u201330.","journal-title":"N Engl J Med"},{"key":"2425_CR19","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.1038\/leu.2014.76","volume":"28","author":"P Guglielmelli","year":"2014","unstructured":"Guglielmelli P, Lasho TL, Rotunno G, Score J, Mannarelli C, Pancrazzi A. et al. The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients. Leukemia. 2014;28:1804\u201310.","journal-title":"Leukemia"},{"key":"2425_CR20","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1182\/bloodadvances.2016000216","volume":"1","author":"A Tefferi","year":"2016","unstructured":"Tefferi A, Lasho TL, Guglielmelli P, Finke CM, Rotunno G, Elala Y. et al. Targeted deep sequencing in polycythemia vera and essential thrombocythemia. Blood Adv. 2016;1:21\u201330.","journal-title":"Blood Adv"},{"key":"2425_CR21","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1182\/blood-2013-11-537167","volume":"123","author":"P Lundberg","year":"2014","unstructured":"Lundberg P, Karow A, Nienhold R, Looser R, Hao-Shen H, Nissen I. et al. Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms. Blood. 2014;123:2220\u20138.","journal-title":"Blood"},{"key":"2425_CR22","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1038\/leu.2008.72","volume":"22","author":"F Cervantes","year":"2008","unstructured":"Cervantes F, Passamonti F, Barosi G. Life expectancy and prognostic factors in the classic BCR\/ABL-negative myeloproliferative disorders. Leukemia. 2008;22:905\u201314.","journal-title":"Leukemia"},{"key":"2425_CR23","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2023.1198834","volume":"14","author":"J Zhang","year":"2023","unstructured":"Zhang J, Shen K, Xiao M, Huang J, Wang J, Wang Y. et al. Case report: application of targeted NGS for the detection of non-canonical driver variants in MPN. Front Genet. 2023;14:1198834.","journal-title":"Front Genet"},{"key":"2425_CR24","doi-asserted-by":"crossref","unstructured":"Nagy A, Neubauer A. Acute myeloid leukemia with myelodysplasia related changes. Atlas Genet Cytogenet Oncol Haematol. 2017-01-01.","DOI":"10.4267\/2042\/68997"},{"key":"2425_CR25","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1182\/blood-2015-07-661835","volume":"127","author":"JD Milosevic Feenstra","year":"2016","unstructured":"Milosevic Feenstra JD, Nivarthi H, Gisslinger H, Leroy E, Rumi E, Chachoua I. et al. Whole-exome sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms. Blood. 2016;127:325\u201332.","journal-title":"Blood"},{"key":"2425_CR26","doi-asserted-by":"publisher","first-page":"3179","DOI":"10.1200\/JCO.2010.34.5298","volume":"29","author":"T Barbui","year":"2011","unstructured":"Barbui T, Thiele J, Passamonti F, Rumi E, Boveri E, Ruggeri M. et al. Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study. J Clin Oncol. 2011;29:3179\u201384.","journal-title":"J Clin Oncol"},{"key":"2425_CR27","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/S0140-6736(05)71142-9","volume":"365","author":"EJ Baxter","year":"2005","unstructured":"Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S. et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365:1054\u201361.","journal-title":"Lancet"},{"key":"2425_CR28","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","volume":"7","author":"RL Levine","year":"2005","unstructured":"Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJP. et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7:387\u201397.","journal-title":"Cancer Cell"},{"key":"2425_CR29","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1038\/s41375-018-0107-z","volume":"32","author":"A Tefferi","year":"2018","unstructured":"Tefferi A, Guglielmelli P, Nicolosi M, Mannelli F, Mudireddy M, Bartalucci N. et al. GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis. Leukemia. 2018;32:1631\u201342.","journal-title":"Leukemia"},{"key":"2425_CR30","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1200\/JCO.2018.78.9867","volume":"36","author":"A Tefferi","year":"2018","unstructured":"Tefferi A, Guglielmelli P, Lasho TL, Gangat N, Ketterling RP, Pardanani A. et al. MIPSS70+ version 2.0: mutation and karyotype-enhanced international prognostic scoring system for primary myelofibrosis. J Clin Oncol. 2018;36:1769\u201370.","journal-title":"J Clin Oncol"},{"key":"2425_CR31","doi-asserted-by":"publisher","first-page":"E5401","DOI":"10.1073\/pnas.1407792111","volume":"111","author":"R Rampal","year":"2014","unstructured":"Rampal R, Ahn J, Abdel-Wahab O, Nahas M, Wang K, Lipson D. et al. Genomic and functional analysis of leukemic transformation of myeloproliferative neoplasms. Proc Natl Acad Sci USA. 2014;111:E5401\u201310.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2425_CR32","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1182\/blood.2019000943","volume":"136","author":"AJ Dunbar","year":"2020","unstructured":"Dunbar AJ, Rampal RK, Levine R. Leukemia secondary to myeloproliferative neoplasms. Blood. 2020;136:61\u201370.","journal-title":"Blood"},{"key":"2425_CR33","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1002\/ajh.27013","volume":"98","author":"L Calabresi","year":"2023","unstructured":"Calabresi L, Carretta C, Romagnoli S, Rotunno G, Parenti S, Bertesi M. et al. Clonal dynamics and copy number variants by single-cell analysis in leukemic evolution of myeloproliferative neoplasms. Am J Hematol. 2023;98:1520\u201331.","journal-title":"Am J Hematol"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02425-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02425-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02425-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T06:03:58Z","timestamp":1732514638000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02425-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,28]]},"references-count":33,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["2425"],"URL":"https:\/\/doi.org\/10.1038\/s41375-024-02425-1","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3468302\/v1","asserted-by":"object"}]},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,28]]},"assertion":[{"value":"20 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"WK, CH, and TH declare part ownership of the MLL Munich Leukemia Laboratory. WW, NN, SH, HM, and MM are employed by the MLL Munich Leukemia Laboratory.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}